MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
12. April 2023 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
27. März 2023 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
15. März 2023 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
08. März 2023 08:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
06. März 2023 16:05 ET
|
MaxCyte, Inc
Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of 31% over full year 2021Fourth quarter 2022 total revenue expected to be approximately $12.4 million,...
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
01. Februar 2023 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
03. Januar 2023 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance...
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
05. Dezember 2022 02:00 ET
|
MaxCyte, Inc
ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform...
MaxCyte Reports Third Quarter 2022 Financial Results
09. November 2022 16:05 ET
|
MaxCyte, Inc
22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, Md., Nov. 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT),...
MaxCyte to Participate in Upcoming Investor Conferences
02. November 2022 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...